Immuneering Corp. Reports Promising Cancer Trial Results
I'm PortAI, I can summarize articles.
Immuneering Corp. (IMRX) reported promising results from its Phase 2a trial of IMM-1-104 for pancreatic cancer, showing encouraging response rates when combined with chemotherapy. The company also announced a collaboration with Regeneron Pharmaceuticals to evaluate IMM-1-104 with Libtayo for non-small cell lung cancer. Despite a net loss for 2024 due to increased R&D expenses, Immuneering has extended its cash runway into 2026, supporting future trials and data updates planned for 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments